Mereo BioPharma
Mereo BioPharma is a clinical-stage company focused on developing & commercialising rare disease & oncology treatments.
45 employees · est. 2015 · London, United Kingdom
Surface Oncology Inc.
#lifeunderthesurface #BBJBestPlacesToWork2023,2022,2021 #BostonGlobeTopPlacesToWork2023,2022,2021
14 employees · est. 2014 · Cambridge, United States
Surface Oncology Inc. is the older company (2015 vs 2014).
Side-by-Side Comparison
| Metric | Mereo BioPharma | Surface Oncology Inc. |
|---|---|---|
| Founded | ||
| Founded | 2015 | 2014 older |
| Headquarters | ||
| Headquarters | London, United Kingdom | Cambridge, United States |
| Employees | ||
| Employees | 45 | 14 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health Care | Biotechnology, Health Care, Life Sciences |
| Funding Stage | ||
| Funding Stage | Post Ipo Equity | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $373.90M | $88.90M |
| Funding Rounds | ||
| Funding Rounds | 6 | 4 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Mereo BioPharma, Biopharmaceutical Company, Oncology Therapeutics, Rare Disease Therapeutics, Etigilimab, Setrusumab, Alvelestat, Clinical Trials, Phase 1a Trial, Phase 2b Trial, COVID-19 Research, Anti-TIGIT, Nivolumab, Osteogenesis Imperfecta, Alpha-1 Antitrypsin Deficiency | Immuno-oncology, Cancer Therapy, TME Biology, Immune System, Antibody Candidates, Cancer Research, Novel Immunotherapy Targets, Tumor Microenvironment, Immune Evasion, Biological Pathways, Clinical-stage, Cancer Treatments, Scientific Founders, Biological Research |
| Website | ||
| Website | mereobiopharma.com | surfaceoncology.com |
About Mereo BioPharma
Mereo Biopharma is a clinical-stage company focused on developing and commercializing rare disease and oncology treatments. Since its founding in 2015, the company has demonstrated an agile and purpose-driven approach to bring novel therapies to market. Through acquisitions from Novartis and AstraZe...
About Surface Oncology Inc.
Surface Oncology Inc. is a clinical-stage immuno-oncology company that was founded in 2014. The company is headquartered in the United States and has recently received a significant $28.90MPost-IPO Equity investment on 20 May 2020 from BVF Partners, EcoR1 Capital, Venrock Healthcare Capital Partners...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at Mereo BioPharma and Surface Oncology Inc. — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at Mereo BioPharma and Surface Oncology Inc. — by email.
Frequently Asked Questions
Compare Mereo BioPharma with someone else
Start typing a company name or domain.